AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GSK Announces $0.4206 Quarterly Dividend with 4.53% Yield
ByAinvest
Saturday, Aug 2, 2025 2:26 pm ET1min read
GSK has declared a quarterly dividend of $0.4206 per share, offering a 4.53% yield. Analysts project a moderate upside for the stock, with a price target range of $34.09 to $45.00, and GuruFocus estimates suggest a significant upside based on the GF Value metric. The average brokerage recommendation is 2.9, indicating a "Hold" status.
GSK plc (GSK) has declared a quarterly dividend of $0.4206 per share, offering a 4.53% yield. This dividend announcement comes on the heels of the company's robust interim results for the second quarter of 2025, where it reported £16 billion in revenue, in line with analyst forecasts, and statutory earnings per share of £0.35, beating expectations [1].Analysts have updated their forecasts in light of these results. They now expect £32.0 billion in revenues and a 53% increase in earnings per share to £1.30 in 2025. The consensus price target remains at £16.52, with a wide range of estimates suggesting a diverse view on possible outcomes for the business. Analysts expect GSK's growth to accelerate, with a forecast 2.1% annualised growth to the end of 2025 [1].
According to MarketBeat, based on 4 analysts' ratings, GSK has a consensus rating of "Hold." The average price target is GBX 1,683.33, with the highest target at GBX 2,000 and the lowest at GBX 1,450. The average price target represents a forecasted upside of 20.41% from the current price of GBX 1,398 [2].
GuruFocus estimates suggest a significant upside based on the GF Value metric. The average brokerage recommendation is 2.9, indicating a "Hold" status [3].
In summary, GSK's quarterly dividend and analyst forecasts provide a mixed outlook. While the dividend offers a moderate yield, the price target range suggests a potential for significant upside. Investors should carefully consider these factors and monitor GSK's performance to make informed investment decisions.
References:
[1] https://www.ainvest.com/news/gsk-plc-interim-report-revenue-line-forecasts-eps-beats-expectations-2508/
[2] https://www.marketbeat.com/stocks/LON/GSK/forecast/
[3] https://www.ainvest.com/news/newmont-corp-divests-orosur-mining-stake-analysts-17-54-upside-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet